"Breakthrough" Devices May Avoid OIG Medicare Fraud Exclusion
This article was originally published in The Gray Sheet
Executive Summary
HHS may be inclined to exempt manufacturers of novel medical devices and drugs from its newly articulated policy of excluding "indirect" health care providers convicted of Medicare fraud, attorney Helen Trilling from the Washington, D.C. law firm of Hogan & Hartson suggested at a recent Food & Drug Law Institute meeting.